These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 21145100)

  • 41. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix.
    Fiorica J; Holloway R; Ndubisi B; Orr J; Grendys E; Boothby R; DeCesare S; LaPolla J; Hoffman M; Patel J
    Gynecol Oncol; 2002 Apr; 85(1):89-94. PubMed ID: 11925125
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A phase II trial of ifosfamide, 5-fluorouracil, and leucovorin in recurrent uterine cervical cancer.
    Stornes I; Mejlholm I; Jakobsen A
    Gynecol Oncol; 1994 Oct; 55(1):123-5. PubMed ID: 7959252
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase I study of paclitaxel, cisplatin, and ifosfamide in patients with recurrent or metastatic squamous cell cancer of the head and neck.
    Benner SE; Lippman SM; Huber MH; Hong WK
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):22-5. PubMed ID: 7481857
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical experience with combination paclitaxel and carboplatin therapy for advanced or recurrent carcinosarcoma of the uterus.
    Toyoshima M; Akahira J; Matsunaga G; Niikura H; Ito K; Yaegashi N; Tase T
    Gynecol Oncol; 2004 Sep; 94(3):774-8. PubMed ID: 15350372
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Paclitaxel and carboplatin in recurrent or metastatic head and neck cancer: a phase II study.
    Fountzilas G; Athanassiadis A; Samantas E; Skarlos D; Kalogera-Fountzila A; Nikolaou A; Bacoyiannis H; Stathopoulos G; Kosmidis P; Daniilidis J
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-65-S2-67. PubMed ID: 9045340
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Carboplatin in combination with raltitrexed in recurrent and metastatic head and neck squamous cell carcinoma: A multicentre phase II study of the Gruppo Oncologico Dell'Italia Meridionale (G.O.I.M.).
    Galetta D; Giotta F; Rosati G; Gebbia V; Manzione L; Di Bisceglie M; Borsellino N; Colucci G
    Anticancer Res; 2005; 25(6C):4445-9. PubMed ID: 16334124
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer.
    Gronlund B; Høgdall C; Hansen HH; Engelholm SA
    Gynecol Oncol; 2001 Oct; 83(1):128-34. PubMed ID: 11585424
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
    Worden FP; Moon J; Samlowski W; Clark JI; Dakhil SR; Williamson S; Urba SG; Ensley J; Hussain MH;
    Cancer; 2006 Jul; 107(2):319-27. PubMed ID: 16779801
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and tolerability of paclitaxel, ifosfamide, and cisplatin as a neoadjuvant chemotherapy in locally advanced cervical carcinoma.
    Scandurra G; Scibilia G; Banna GL; D'Agate G; Lipari H; Gieri S; Scollo P
    J Gynecol Oncol; 2015 Apr; 26(2):118-24. PubMed ID: 25686397
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase II study of paclitaxel in combination with carboplatin for patients with recurrent or persistent uterine sarcoma.
    Yoo HJ; Lim MC; Lim S; Park JY; Kang S; Park SY; Seo SS
    Arch Gynecol Obstet; 2012 Dec; 286(6):1529-35. PubMed ID: 22825691
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A phase II study of ifosfamide, carboplatin and cisplatin in advanced and recurrent squamous cell carcinoma of the uterine cervix.
    Filtenborg TA; Hansen HH; Aage Engelholm S; Rørth M
    Ann Oncol; 1993 Jun; 4(6):485-8. PubMed ID: 8353091
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adjuvant combined paclitaxel and carboplatin chemotherapy for glassy cell carcinoma of the uterine cervix: report of three cases with clinicopathological analysis.
    Takahashi Y; Sasaki H; Mogami H; Hamada S; Konishi I
    J Obstet Gynaecol Res; 2011 Dec; 37(12):1860-3. PubMed ID: 21955049
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA).
    Simpkins F; Drake R; Escobar PF; Nutter B; Rasool N; Rose PG
    Gynecol Oncol; 2015 Feb; 136(2):240-5. PubMed ID: 25485782
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Low-dose fractionated radiation and chemotherapy prior to definitive chemoradiation in locally advanced carcinoma of the uterine cervix: Results of a prospective phase II clinical trial.
    Das S; Subhashini J; Rami Reddy JK; KantiPal S; Isiah R; Oommen R
    Gynecol Oncol; 2015 Aug; 138(2):292-8. PubMed ID: 26013695
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot study.
    Nagao S; Fujiwara K; Oda T; Ishikawa H; Koike H; Tanaka H; Kohno I
    Gynecol Oncol; 2005 Mar; 96(3):805-9. PubMed ID: 15721429
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combination of ifosfamide, paclitaxel, and cisplatin for the treatment of metastatic and recurrent carcinoma of the uterine cervix: a phase II study of the Hellenic Cooperative Oncology Group.
    Dimopoulos MA; Papadimitriou CA; Sarris K; Aravantinos G; Kalofonos C; Gika D; Gourgoulis GM; Efstathiou E; Skarlos D; Bafaloukos D
    Gynecol Oncol; 2002 Jun; 85(3):476-82. PubMed ID: 12051877
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A feasibility study of carboplatin and weekly paclitaxel combination chemotherapy in endometrial cancer: a Kansai Clinical Oncology Group study (KCOG0015 trial).
    Ito K; Tsubamoto H; Itani Y; Kuroboshi H; Fujita H; Nobunaga T; Coleman RL
    Gynecol Oncol; 2011 Feb; 120(2):193-7. PubMed ID: 21075434
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prediction of progression-free survival and response to paclitaxel plus carboplatin in patients with recurrent or advanced cervical cancer.
    Hisamatsu T; Mabuchi S; Yoshino K; Fujita M; Enomoto T; Hamasaki T; Kimura T
    Int J Gynecol Cancer; 2012 May; 22(4):623-9. PubMed ID: 22343974
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Primary analysis.
    Ishikawa M; Shibata T; Iwata T; Nishio S; Takada T; Suzuki S; Horie K; Kudaka W; Kagabu M; Tanikawa M; Kitagawa R; Takekuma M; Kobayashi H; Yaegashi N;
    Gynecol Oncol; 2021 Aug; 162(2):292-298. PubMed ID: 34016453
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Second platinum therapy in patients with uterine cervical cancer previously treated with platinum chemotherapy.
    Tanioka M; Katsumata N; Yonemori K; Kouno T; Shimizu C; Tamura K; Ando M; Fujiwara Y
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):337-42. PubMed ID: 20976599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.